Viking Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Viking Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 29.4% bzw. 69.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 31.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -111.9% betragen.
Wichtige Informationen
29.4%
Wachstumsrate der Gewinne
31.44%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.3% |
| Wachstumsrate der Einnahmen | 69.6% |
| Zukünftige Eigenkapitalrendite | -111.93% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 06 Jul 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Seeking Alpha • Jun 30
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Summary Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current ~$5B valuation amid sector momentum. Novo Nordisk’s oral Wegovy launch sets a new benchmark, highlighting peptide-based oral GLP-1 drugs’ commercial potential and raising the value of VKTX’s oral program. VKTX’s injectable VK2735 faces intensified competition after Eli Lilly’s Retatrutide Phase III results, which establish a higher efficacy standard (>24%). I await VKTX’s upcoming oral maintenance study for clarity on tolerability and commercial positioning before reconsidering a Buy stance. Read the full article on Seeking AlphaAnalyseartikel • Jun 20
Viking Therapeutics (VKTX) Stock Could Be 67.2% Undervalued After Analysts Back VK2735
Executive change adds experience to Viking Therapeutics' clinical ambitions Viking Therapeutics (VKTX) recently drew fresh attention after analyst reports highlighted the potential of obesity drug candidate VK2735, and the company added further depth by appointing Hubert C. Chen, M.D., as chief medical officer. For investors watching Viking Therapeutics stock, Dr. Chen’s background across drug discovery, clinical development, and regulatory strategy adds another layer to the story around...
Neues Narrativ • Mar 19
Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play
Catalysts About Viking Therapeutics Viking Therapeutics focuses on developing therapies for obesity and related cardiometabolic conditions, with VK2735 as its lead dual GLP-1 and GIP receptor agonist program in both injectable and oral forms. What are the underlying business or industry changes driving this perspective?
Neues Narrativ • Mar 05
Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis
Catalysts About Viking Therapeutics Viking Therapeutics is a clinical stage biopharmaceutical company focused on therapies for obesity and related metabolic disorders. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 15
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
Summary 13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market. The global non-alcoholic steatohepatitis treatment market size is projected to reach $92.5 billion by 2034. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring
Summary Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 represents the best efficacy and safety profile ever reported for an oral GLP-1 drug. The oral obesity market is projected to be the fastest-growing segment within the broader weight-loss market, driven by the superior convenience of oral formulations compared to injectable treatments. Similar read-outs, the option market and current valuation of VKTX of $3.64 Bn imply huge stock price upside to $52 upon positive trial data. Read the full article on Seeking AlphaAnalyseartikel • Dec 23
We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Viking Therapeutics...Seeking Alpha • Dec 19
Viking Therapeutics: Holiday Gift
Summary Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed impressive weight loss results and tolerability, with potential advantages over current weekly injectable treatments. Concerns about manufacturing costs and scalability exist, but Viking's strong pipeline and market potential in obesity make it a compelling investment. Analysts remain bullish, with the average price target at $110, reflecting a substantial upside potential of 187% from current levels. Read the full article on Seeking AlphaSeeking Alpha • Dec 05
Viking Stock Pops, Then Drops On Latest Obesity/MASH Data: Why I'm Still Bullish
Summary Viking Therapeutics is a strong contender in the GLP-1 obesity drug market - candidate VK2735 has the potential to challenge Eli Lilly's Zepbound and Novo Nordisk's Wegovy. The latest data from the oral and subcu versions of Viking's drug are encouraging, albeit pivotal studies must still be arranged and negotiated successfully. If approved, VK2735 will need to show it has a best-in-class profile in terms of either durability, dosing regimen, side effect profile, price or mode of administration. Despite manufacturing concerns, Viking's potential for blockbuster revenues and competitive differentiation makes it an attractive M&A target for Big Pharma. I'm not changing my buy rating on Viking as its GLP candidate looks likely to be the next to join commercial markets, and if M&A does happen, I suspect Viking would command a price >$10bn. Read the full article on Seeking AlphaSeeking Alpha • Nov 04
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Summary Viking Therapeutics' oral VK2735 reported strong weight loss and good safety and tolerability in the phase 1 trial, with the 100mg dose achieving 8.2% absolute weight loss in four weeks. These results put Viking at the front of the oral obesity field, but with a major caveat of rapid treatment landscape evolution. The sell news reaction is understandable given high investor excitement ahead of the data update, and the fact there are no meaningful catalysts until at least Q4 2025. While the stock may consolidate in the near-term, the long-term outlook has improved for Viking after new oral VK2735 data. Read the full article on Seeking AlphaSeeking Alpha • Oct 28
Viking Therapeutics: Lots Of Positives
Summary Viking Therapeutics' VK2735 drug shows promising weight-loss results, driving a stock rally and positive analyst sentiment due to its potential in a $40 billion market. The company plans to escalate VK2735 dosages and start Phase 2 trials, with Phase 3 trials for the injectable version and VK2809 NASH drug also in the pipeline. The stock has a market cap below $9 billion while larger competitors have seen stock valuations soar by multiples of these levels indicating the opportunity for Viking Therapeutics. Read the full article on Seeking AlphaSeeking Alpha • Sep 25
Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Summary Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to Novo Nordisk's Wegovy and Eli Lilly's Zepbound, pitching it to one day compete in a >$150bn market. Viking's strong financial position, upcoming Phase 3 trials, and potential oral formulation of VK-2735 justify upgrading the stock to a “Buy.”. The company's secondary NASH candidate, VK2809, provides a hedge against risks, adding to Viking's investment appeal. It should be noted that VK2735 data is immature and there are many more tests to come — upcoming data from a Phase 1 study of oral VK2735 is a potentially significant catalyst for upside. Read the full article on Seeking AlphaAnalyseartikel • Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 30
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Summary Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations. Despite competition from Eli Lilly and Novo Nordisk, VK2735's unique oral formulation could position Viking as a strong contender in the obesity drug market. VKTX's financial stability, with $942 million in cash and equivalents, supports its ongoing and future clinical trials, making it a viable long-term investment. I rate Viking Therapeutics as a "Buy" for high-risk tolerant investors, driven by VK2735's potential and additional upside from VK2809 and preclinical assets. Read the full article on Seeking AlphaSeeking Alpha • Jul 25
Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Summary Viking Therapeutics, Inc. provided a better-than-expected pipeline update when it reported second quarter earnings. Subcutaneous VK2735 will advance straight into a phase 3 trial, and this should speed up its potential market arrival by at least 18–24 months. Oral VK2735 has advanced to the 100mg cohort, with management making positive remarks about tolerability in the 60mg and 80mg dose cohorts. A novel amylin candidate was added to the pipeline with an IND submission expected in 2025. These updates strengthen both the standalone and M&A investment thesis on Viking Therapeutics. Read the full article on Seeking AlphaAnalyseartikel • Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Viking...Seeking Alpha • Apr 02
Viking Therapeutics: Future Weight Loss Heavyweight?
Summary Viking Therapeutics' share price has rapidly increased from recent weight loss drug excitement. The company’s value seems to be derived from its weight loss and NASH/MASH candidates. VK2735, the weight loss candidate, presents a potentially massively large opportunity, despite the crowded market. VK2809, the NASH/MASH candidate, now offers an attractive opportunity as a recently launched drug provides proof-of-concept for the space. Read the full article on Seeking AlphaAnalyseartikel • Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Viking Therapeutics...Analyseartikel • Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Viking Therapeutics...Analyseartikel • Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 141 | -499 | -565 | -458 | 16 |
| 12/31/2027 | N/A | -587 | -520 | -502 | 17 |
| 12/31/2026 | N/A | -563 | -571 | -509 | 17 |
| 3/31/2026 | N/A | -472 | -340 | -340 | N/A |
| 12/31/2025 | N/A | -360 | -279 | -279 | N/A |
| 9/30/2025 | N/A | -237 | -225 | -225 | N/A |
| 6/30/2025 | N/A | -172 | -153 | -153 | N/A |
| 3/31/2025 | N/A | -128 | -134 | -134 | N/A |
| 12/31/2024 | N/A | -110 | -88 | -88 | N/A |
| 9/30/2024 | N/A | -99 | -74 | -74 | N/A |
| 6/30/2024 | N/A | -97 | -72 | -72 | N/A |
| 3/31/2024 | N/A | -94 | -55 | -55 | N/A |
| 12/31/2023 | N/A | -86 | -73 | -73 | N/A |
| 9/30/2023 | N/A | -81 | -67 | -67 | N/A |
| 6/30/2023 | N/A | -74 | -61 | -61 | N/A |
| 3/31/2023 | N/A | -72 | -63 | -63 | N/A |
| 12/31/2022 | N/A | -69 | -48 | -48 | N/A |
| 9/30/2022 | N/A | -62 | -50 | -50 | N/A |
| 6/30/2022 | N/A | -59 | -47 | -47 | N/A |
| 3/31/2022 | N/A | -57 | -47 | -47 | N/A |
| 12/31/2021 | N/A | -55 | -48 | -48 | N/A |
| 9/30/2021 | N/A | -54 | -41 | -41 | N/A |
| 6/30/2021 | N/A | -50 | -35 | -35 | N/A |
| 3/31/2021 | N/A | -44 | -28 | -28 | N/A |
| 12/31/2020 | N/A | -39 | -22 | -22 | N/A |
| 9/30/2020 | N/A | -36 | -28 | -28 | N/A |
| 6/30/2020 | N/A | -32 | -26 | -26 | N/A |
| 3/31/2020 | N/A | -31 | -26 | -26 | N/A |
| 12/31/2019 | N/A | -26 | N/A | -25 | N/A |
| 9/30/2019 | N/A | -24 | N/A | -16 | N/A |
| 6/30/2019 | N/A | -24 | N/A | -18 | N/A |
| 3/31/2019 | N/A | -23 | N/A | -17 | N/A |
| 12/31/2018 | N/A | -22 | N/A | -19 | N/A |
| 9/30/2018 | N/A | -21 | N/A | -20 | N/A |
| 6/30/2018 | N/A | -20 | N/A | -18 | N/A |
| 3/31/2018 | N/A | -19 | N/A | -17 | N/A |
| 12/31/2017 | N/A | -21 | N/A | -15 | N/A |
| 9/30/2017 | N/A | -20 | N/A | -13 | N/A |
| 6/30/2017 | N/A | -18 | N/A | -13 | N/A |
| 3/31/2017 | N/A | -16 | N/A | -12 | N/A |
| 12/31/2016 | N/A | -15 | N/A | -11 | N/A |
| 9/30/2016 | N/A | -16 | N/A | -12 | N/A |
| 6/30/2016 | N/A | -17 | N/A | -13 | N/A |
| 3/31/2016 | N/A | -21 | N/A | -11 | N/A |
| 12/31/2015 | N/A | -23 | N/A | -9 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: VKTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: VKTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: VKTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: VKTX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Hohe Wachstumseinnahmen: VKTX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: VKTX wird voraussichtlich in 3 Jahren unrentabel sein.
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/10 00:07 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Viking Therapeutics, Inc. wird von 32 Analysten beobachtet. 17 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |